Table 2.

Monoclonal antibodies (excluding anti-EGFR agents) in clinical development in head and neck cancer [40].

Agent	Phase	Status	Study Type	Description
Bevacizumab	Clinicaltrials.gov search retrieves records for 3 phase 1 trials 2 phase 1/2 trials 11 phase 2 trials 1 phase 3 trial	The phase 1, 1/2, and 2 trials are completed or ongoing The phase 3 trial is recruiting	Several	The early-phase trials are exploring several different regimens The phase 3 trial is a multicenter, randomized, controlled trial in which patients with recurrent or metastatic HNSCC receive chemotherapy ± bevacizumab. Chemotherapy consists of cisplatin, docetaxel, and fluorouracil.
anti-CD45 MAb	1 (NCT00608257)	Completed (N = 18)	Dose-escalation study	Patients with EBV-positive nasopharyngeal cancer receive autologous EBV-specific cytotoxic T cells in combination with anti-CD45 MAb
MN-14 (anti-CEA MAb)	1/2 (NCT00004048)	Active, not recruiting(N ~ 30)	Dose-escalation study	Patients with medullary thyroid cancer undergo radioimmunotherapy with MN-14 alone or combined with doxorubicin and peripheral blood stem cell rescue

CEA: carcinoembryonic antigen; EBV: Epstein-Barr virus; HNSCC: head and neck squamous cell carcinoma; MAb: monoclonal antibody.